Last updated: February 23, 2026
What is NDC 24689-0132?
The drug with NDC 24689-0132 is Repatha (evolocumab), a PCSK9 inhibitor approved by the FDA in August 2017 for lowering LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional LDL reduction.
Repatha is marketed by Amgen. It is administered via subcutaneous injection, typically once every two or four weeks.
Market Size and Demand Drivers
Pharmacological Profile
| Attribute |
Details |
| Drug Class |
PCSK9 inhibitor |
| Indication |
Hypercholesterolemia, cardiovascular risk reduction |
| Administration |
Subcutaneous injection (every 2-4 weeks) |
| Approved Uses |
Heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease |
Market Penetration & Competition
Repatha competes primarily with:
- Alirocumab (Praluent) by Sanofi/Regeneron
- Statins (first-line treatment)
- Other emerging PCSK9 inhibitors, such as inclisiran
The global market for PCSK9 inhibitors stood at approximately $7.5 billion in 2022. Repatha’s market share in Pharmerging markets is expanding, while U.S. sales remain dominant due to early adoption and reimbursement policies.
US Market Size
In 2022, US sales of Repatha were valued at roughly $2.6 billion, sourced from IQVIA data. Despite competitive pressure, demand remains resilient among high-risk patient populations.
Key Drivers include:
- Guidelines endorsing PCSK9 inhibitors for high-risk patients
- Growing prevalence of hypercholesterolemia and cardiovascular disease
- Uptake in secondary prevention populations
Pricing Landscape
Current Pricing Model
Amgen's wholesale acquisition cost (WAC) for Repatha is approximately $5,850 per year for the 140 mg dose administered biweekly. Commercial insurers often negotiate discounts.
Price Comparison with Competitors
| Drug |
WAC (Annual) |
Administration Schedule |
Approval Year |
| Repatha (evolocumab) |
~$5,850 |
140 mg every 2 weeks or 420 mg monthly |
2017 |
| Praluent (alirocumab) |
~$4,500 |
75 mg every 2 weeks, can be increased to 150 mg |
2015 |
| Inclisiran |
~$6,100 |
300 mg administered twice a year after initial doses |
2020 |
Reimbursement and Discounts
- Discounts up to 20-30% are common via pharmacy benefit managers.
- Medicare Part D covers Repatha but with prior authorization.
- Patient assistance programs reduce out-of-pocket costs, impacting net revenue.
Future Price Projections
Short-Term Factors (1-3 years)
- Reimbursement policies: Ongoing negotiations may stabilize or reduce net prices.
- Market penetration: As physicians adopt Repatha more widely for primary prevention, sales volume increases with moderate price adjustments.
- Contracting strategies: Amgen's focus on payer discounts and patient access programs controls gross-to-net pricing.
Expected average net price after discounts: $4,200 - $4,800 per year.
Long-Term Factors (3-5 years)
- Biosimilars and generics: No biosimilar available yet, but regulatory developments could influence pricing by 2025.
- Market competition: Inclisiran (by Novartis) introduces twice-yearly dosing, potentially attracting different patient segments.
- Regulatory pressure: Price caps and value-based pricing models aim for reductions of 15-20%.
Projected average net price in 2025: $3,800 - $4,200 per year, with further reductions possible through increased competition and policy shifts.
Revenue Forecasts
| Year |
Sales Estimate |
Notes |
| 2023 |
~$2.7 billion |
Stable sales with moderate growth |
| 2024 |
~$3.0 billion |
Increased adoption; price stabilization |
| 2025 |
~$3.3 billion |
Market expansion and price adjustments |
Key Takeaways
- Repatha remains a high-value, high-price therapy with an annual list price of ~$5,850.
- Net pricing is typically reduced by 15-30% due to discounts, leading to an average net price of approximately $4,200.
- The potential for future price reduction exists, driven by increased competition, biosimilar entry, and policy measures.
- Demand growth is expected to align with cardiovascular disease prevalence, especially among high-risk patients.
- Market share gains depend heavily on reimbursement dynamics and physician adoption.
FAQs
Q1: How does Repatha’s pricing compare globally?
Pricing varies significantly: in Europe, list prices are notably lower, often around €3,000-€4,000 annually, influenced by national pricing policies and negotiations.
Q2: What factors could significantly reduce Repatha’s price?
Entry of biosimilars, regulatory price caps, and value-based agreements with payers.
Q3: How does patient access impact revenue?
Insurance coverage levels and patient assistance programs influence net prices and overall market size.
Q4: Are there upcoming patent expirations?
Repatha’s original patent protections extend into the late 2020s, delaying biosimilar competition.
Q5: What other competitive therapies could impact Repatha’s market?
Inclisiran, a once-twice-yearly injectable, aims to capture patient segments seeking less frequent dosing.
References
- IQVIA. (2022). Pharmaceutical Sales Data.
- U.S. Food and Drug Administration. (2017). Repatha (evolocumab) approval letter.
- Amgen. (2022). Repatha Product Information.
- Novartis. (2020). Inclisiran FDA approval and market outlook.
- European Medicines Agency. (2021). Summary of Product Characteristics for Repatha.
